alefacept

Known as: alefacept [Chemical/Ingredient], LFA3TIP, LFA-3 IgG(1) fusion protein 
A recombinant dimeric fusion protein consisting of the extracellular CD2-binding domain of the human leukocyte function-associated antigen 3 (LFA-3… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Type 1 diabetes (T1D) results from destruction of pancreatic β cells by autoreactive effector T cells. We hypothesized… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Memory T cells promote allograft rejection particularly in co-stimulation blockade–based immunosuppressive regimens. Here we show… (More)
  • figure 1
  • figure 2
Is this relevant?
2009
2009
Alefacept (Amevive) is an immunosuppressive dimeric fusion protein that is used for psoriasis control. We recently showed its… (More)
  • table 1
  • figure 2
  • figure 1
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVE To evaluate the efficacy and safety of alefacept in combination with methotrexate (MTX) for the treatment of psoriatic… (More)
Is this relevant?
Review
2005
Review
2005
Alefacept is a selective immunomodulating, antipsoriatic drug that blocks the LFA-3/CD2 interaction necessary for the activation… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Alefacept, human lymphocyte function-associated antigen 3/immunoglobulin 1 fusion protein, binds to CD2 molecules on… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2003
2003
Alefacept is the first biologic agent approved for the treatment of chronic plaque psoriasis in the United States. Alefacept… (More)
Is this relevant?
2003
2003
OBJECTIVE To examine the relationship between the pharmacodynamic and antipsoriatic effects of alefacept, a biologic agent that… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND In previous phase II studies, alefacept significantly improved psoriasis and was well tolerated. The clinical response… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND Psoriatic plaques are characterized by infiltration with CD4+ CD45RO+ and CD8+ CD45RO+ memory effector T lymphocytes… (More)
Is this relevant?